Novo Nordisk's weight loss medication, Wegovy, which has been available in Germany for a year, is under scrutiny due to new research highlighting a potential side effect: hair loss. The active ingredient, semaglutide, is also used in the diabetes treatment Ozempic. While the association between semaglutide and hair loss is not new, a recent study conducted by researchers at the University of British Columbia provides further evidence of this risk.
The study compared the incidence of hair loss in nearly 2,300 patients, with 1,926 using semaglutide and 1,348 using Contrave, an older weight loss medication. Findings indicated that semaglutide users had a 52% higher risk of hair loss than those using Contrave, with women facing a more than twofold increased risk. However, the researchers acknowledged that their data primarily involved female patients, making it difficult to draw firm conclusions about gender differences.
The researchers noted several factors that may contribute to the increased risk of hair loss among semaglutide users, including rapid weight loss, potential nutrient deficiencies, and hormonal shifts. They emphasized that further research is needed to determine whether hair loss persists after discontinuing semaglutide.
Novo Nordisk maintains confidence in the safety profile of its GLP-1 medications when used appropriately. Patients considering semaglutide for weight loss are advised to weigh the potential risk of hair loss against the benefits, particularly those with diabetes or morbid obesity, who may have different risk-benefit considerations. This ongoing study underscores the importance of continued evaluation of the long-term effects of popular weight loss drugs.